- PR Newswire•9 days ago
SAN DIEGO, March 20, 2017 /PRNewswire/ -- NuVasive, Inc. (NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced updated guidance from the National Industry for Clinical Excellence (NICE) in the U.K. for lateral interbody fusion in the lumbar spine. NICE stated the evidence on efficacy for lateral interbody fusion is adequate in quality and quantity and the procedure may be used provided that standard arrangements are in place for clinical governance, consent and audit. The majority of the evidence submitted to and reviewed by the panel was peer-reviewed journal articles describing the now 14-year experience with and outcomes following the Company's eXtreme Lateral Interbody Fusion (XLIF®) procedure, the leading global lateral approach spine surgical technique.
- Zacks•14 days ago
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire•27 days ago
NuVasive, Inc. (NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.
NUVA : Summary for NuVasive, Inc. - Yahoo Finance
NuVasive, Inc. (NUVA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||64.53 x 100|
|Day's Range||74.23 - 75.31|
|52 Week Range||47.73 - 76.31|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||109.12|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|